Brief: Aker Biomarine Q2 Adjusted EBITDA USD 12.9 Million
10/07/2026 06:08
BRIEF-Aker Biomarine Q2 Adjusted EBITDA USD 12.9 Million July 10 (Reuters) - Aker Biomarine ASA AKBM.OL:
Q2 ADJUSTED EBITDA USD 12.9 MILLION
Q2 REVENUE USD 57.9 MILLION
SEES CONTINUED YEAR-OVER-YEAR GROWTH AND IMPROVED PROFITS, SUPPORTED BY GOOD UNDERLYING DEMAND ACROSS MULTIPLE MARKETS
IN CONSUMER HEALTH PRODUCTS, REVENUES ARE EXPECTED TO RETURN TO MODEST GROWTH
UNDERSTORY SALES PROCESS IS STILL ONGOING WITH ADVANCED DISCUSSIONS WITH ONE INTERESTED PARTY
LOKEY AS INVESTMENT BANKS TO SUPPORT COMPANY IN EXPLORING CERTAIN INTEREST IN HUMAN HEALTH INGREDIENT BUSINESS UNIT
Source text: ID:nObifZTw1a
Further company coverage: AKBM.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Aker Biomarine ASA
See all newsBrief: Aker ASA: Conditions For Completion Of Merger With Aker Biomarine Satisfied
Brief: Aker Capital Buys 933,110 Aker BioMarine Shares
Brief: Aker Biomarine To Hold EGM On August 17
Brief: Aker Biomarine: Optional Cash Offer To Shareholders
Brief: Aker Biomarine: Proposed Merger And Optional Cash Offer